Stepwise-activable multifunctional peptide-guided prodrug micelles for cancerous cells intracellular drug release
Source abstract
Abstract
A novel type of stepwise-activable multifunctional peptide-guided prodrug micelles (MPPM) was fabricated for cancerous cells intracellular drug release. Deca-lysine sequence (K10), a type of cell-penetrating peptide, was synthesized and terminated with azido-glycine. Then a new kind of molecule, alkyne modified doxorubicin (DOX) connecting through disulfide bond (DOX-SS-alkyne), was synthesized. After coupling via Cu-catalyzed azide–alkyne cycloaddition (CuAAC) click chemistry reaction, reduction-sensitive peptide-guided prodrug was obtained. Due to the amphiphilic property of the prodrug, it can assemble to form micelles. To prevent the nanocarriers from unspecific cellular uptake, the prodrug micelles were subsequently modified with 2,3-dimethyl maleic anhydride to obtain MPPM with a negatively charged outer shell. In vitro studies showed that MPPM could be shielded from cells under psychological environment. However, when arriving at mild acidic tumor site, the cell-penetrating capacity of MPPM would be activated by charge reversal of the micelles via hydrolysis of acid-labile β-carboxylic amides and regeneration of K10, which enabled efficient internalization of MPPM by tumor cells as well as following glutathione- and protease-induced drug release inside the cancerous cells. Furthermore, since the guide peptide sequences can be accurately designed and synthesized, it can be easily changed for various functions, such as targeting peptide, apoptotic peptide, even aptamers, only need to be terminated with azido-glycine. This method can be used as a template for reduction-sensitive peptide-guided prodrug for cancer therapy. A novel type of stepwise-activable multifunctional peptide-guided prodrug micelles (MPPM) was fabricated for selective drug delivery in cancerous cells. MPPM could be shielded from cells under psychological environment. However, when arriving at mild acidic tumor site, the cell-penetrating capacity of MPPM would be activated by charge reversal of the prodrug micelles via hydrolysis of acid-labile β-carboxylic amides and regeneration of K10. The cell-penetrating peptide, K10, would enable efficient internalization of MPPM by tumor cells, and the drug would be rapidly released induced by concentrated glutathione and numerous proteases inside the cancerous cells, resulting in the inhibited effect of the cells .
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (22)
Show source-provided references
1. Barbé C, Bartlett J, Kong L, Finnie K, Lin HQ, Larkin M, Calleja S, Bush A, Calleja G (2004) Silica particles: a novel drug-delivery system. Adv Mater 16:1959–196610.1002/adma.200400771 ↗
2. Brown SD, Nativo P, Smith J, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ (2010) Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc 132:4678–468410.1021/ja908117a ↗
3. Chen WH, Chen JX, Cheng H, Chen CS, Yang J, Xu XD, Wang Y, Zhuo RX, Zhang XZ (2013) A new anti-cancer strategy of damaging mitochondria by pro-apoptotic peptide functionalized gold nanoparticles. Chem Commun 49:6403–640510.1039/c3cc43283a ↗
4. Chen JX, Xu XD, Chen WH, Zhang XZ (2014) Multi-functional envelope-type nanoparticles assembled from amphiphilic peptidic prodrug with improved anti-tumor activity. ACS Appl Mater Interfaces 6:593–59810.1021/am404680n ↗
5. Chen WH, Lei Q, Yang CX, Jia HZ, Luo GF, Wang XY, Liu G, Cheng SX, Zhang XZ (2015) Bioinspired nano-prodrug with enhanced tumor targeting and increased therapeutic efficiency. Small 11:5203–5242
6. Gillies ER, Fréchet JMJ (2005) Dendrimers and dendritic polymers in drug delivery. Drug Discovery Today 10:35–4310.1016/S1359-6446(04)03276-3 ↗
7. He QJ, Gao Y, Zhang LX, Zhang ZW, Gao F, Ji XF, Li YP, Shi JL (2011) A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 32:7711–772010.1016/j.biomaterials.2011.06.066 ↗
8. Huang P, Wang DL, Su Y, Huang W, Zhou YF, Cui DX, Zhu XY, Yan DY (2014) Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug–drug conjugate for cancer therapy. J Am Chem Soc 136:11748–1175610.1021/ja505212y ↗
9. Jin YL, Huang YY, Yang H, Liu GQ, Zhao R (2015) A peptide-based pH-sensitive drug delivery system for targeted ablation of cancer cells. Chem Commun 51:14454–1445710.1039/C5CC05184C ↗
10. Koo AN, Lee HJ, Kim SE, Chang JH, Park C, Kim C, Park JH, Lee SC (2008) Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery. Chem Commun 48:6570–657210.1039/b815918a ↗
11. Qin SY, Xu XD, Chen CS, Chen JX, Li ZY, Zhuo RX, Zhang XZ (2011) Supramolecular architectures self-assembled from asymmetrical hetero cyclopeptides. Macromol Rapid Commun 32:758–76410.1002/marc.201100052 ↗
12. Shi CL, Guo X, Qu QQ, Tang ZM, Wang Y, Zhou SB (2014) Actively targeted delivery of anticancer drug to tumor cells by redox-responsive star-shaped micelles. Biomaterials 35:8711–872210.1016/j.biomaterials.2014.06.036 ↗
13. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discovery 4:145–16010.1038/nrd1632 ↗
14. Verma A, Simard JM, Worrall JWE, Rotello VM (2004) Tunable reactivation of nanoparticle-inhibited beta-galactosidase by glutathione at intracellular concentrations. J Am Chem Soc 126:13987–1399110.1021/ja046572r ↗
15. Vicent MJ, Duncan R (2006) Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 24:39–4710.1016/j.tibtech.2005.11.006 ↗
16. Xiao W, Chen WH, Xu XD, Li C, Zhang J, Zhuo RX, Zhang XZ (2011) Design of a cellular-uptake-shielding “plug and play” template for photo controllable drug release. Adv Mater 23:3526–353010.1002/adma.201101806 ↗
17. Xue XD, Jin SB, Zhang CQ, Yang KN, Huo SD, Chen F, Zou GZ, Liang XJ (2015) Probe-inspired nano-prodrug with dual-color fluorogenic property reveals spatiotemporal drug release in living cells. ACS Nano 9:2729–273910.1021/nn5065452 ↗
18. Zhang J, Xu XD, Liu Y, Liu CW, Chen XH, Li C, Zhuo RX, Zhang XZ (2012) Design of an “active defense” system as drug carriers for cancer therapy. Adv Funct Mater 22:1704–171010.1002/adfm.201102132 ↗
19. Zhang J, Yuan ZF, Wang Y, Chen WH, Luo GF, Cheng SX, Zhuo RX, Zhang XZ (2013) Multifunctional envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery. J Am Chem Soc 135:5068–507310.1021/ja312004m ↗
20. Zhang P, Sun F, Tsao C, Liu S, Jain P, Sinclair A, Hung HC, Bai T, Wu K, Jiang S (2015a) Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics and reduces immunogenicity. PNAS 112:12046–1205110.1073/pnas.1512465112 ↗
21. Zhang J, Wu D, Li MF, Feng J (2015b) Multifunctional mesoporous silica nanoparticles based on charge-reversal plug-gate nanovalves and acid-decomposable ZnO quantum dots for intracellular drug delivery. ACS Appl Mater Interfaces 7:26666–2667310.1021/acsami.5b08460 ↗
22. Zhou ZX, Shen YQ, Tang JB, Fan MH, Kirk EAV, Murdoch WJ, Radosz M (2009) Charge-reversal drug conjugate for targeted cancer cell nuclear drug delivery. Adv Funct Mater 19:3580–358910.1002/adfm.200900825 ↗